LifeSci Capital analyst Sam Slutsky has maintained their neutral stance on IFRX stock, giving a Hold rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sam Slutsky has given his Hold rating due to a combination of factors surrounding InflaRx’s current market position and strategic developments in the pharmaceutical industry. The recent licensing deal between Biogen and Vanqua Bio for an oral C5aR1 inhibitor highlights the growing interest in this therapeutic area, which is relevant to InflaRx’s own pipeline. However, there is uncertainty regarding the central nervous system (CNS) penetrance of InflaRx’s INF904, which could impact its competitive edge in the market.
Additionally, the financial metrics of InflaRx, such as its cash burn rate and the years of cash available, suggest a stable but cautious outlook. While the company has more than 1.5 years of cash available, the short interest remains low, indicating limited immediate pressure from investors. These elements collectively contribute to a Hold rating, reflecting a balanced view of potential opportunities and existing uncertainties.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $1.00 price target.